BR112021008316A2 - derivados de xantina substituída - Google Patents
derivados de xantina substituída Download PDFInfo
- Publication number
- BR112021008316A2 BR112021008316A2 BR112021008316-2A BR112021008316A BR112021008316A2 BR 112021008316 A2 BR112021008316 A2 BR 112021008316A2 BR 112021008316 A BR112021008316 A BR 112021008316A BR 112021008316 A2 BR112021008316 A2 BR 112021008316A2
- Authority
- BR
- Brazil
- Prior art keywords
- mmol
- mixture
- added
- esi
- disorder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18212060.0 | 2018-12-12 | ||
| EP18212060 | 2018-12-12 | ||
| PCT/EP2019/084375 WO2020120450A1 (en) | 2018-12-12 | 2019-12-10 | Substituted xanthine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021008316A2 true BR112021008316A2 (pt) | 2021-08-03 |
Family
ID=64665184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021008316-2A BR112021008316A2 (pt) | 2018-12-12 | 2019-12-10 | derivados de xantina substituída |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11198696B2 (https=) |
| EP (1) | EP3894410B1 (https=) |
| JP (1) | JP7502299B2 (https=) |
| KR (1) | KR102877857B1 (https=) |
| CN (1) | CN113166151B (https=) |
| AU (1) | AU2019396499B2 (https=) |
| BR (1) | BR112021008316A2 (https=) |
| CL (1) | CL2021001509A1 (https=) |
| DK (1) | DK3894410T3 (https=) |
| EA (1) | EA202191588A1 (https=) |
| ES (1) | ES2964630T3 (https=) |
| HU (1) | HUE064908T2 (https=) |
| IL (1) | IL283768B2 (https=) |
| MX (1) | MX2021007019A (https=) |
| PH (1) | PH12021551345A1 (https=) |
| PL (1) | PL3894410T3 (https=) |
| TW (1) | TWI825243B (https=) |
| WO (1) | WO2020120450A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12064917B2 (en) | 2012-11-21 | 2024-08-20 | Stratasys, Inc. | Method for printing three-dimensional parts with cyrstallization kinetics control |
| HUE064908T2 (hu) * | 2018-12-12 | 2024-04-28 | Boehringer Ingelheim Int | Szubsztituált xantinszármazékok |
| WO2024164818A1 (zh) * | 2023-02-08 | 2024-08-15 | 中国科学院上海药物研究所 | 黄嘌呤类化合物及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107082782B (zh) | 2013-03-15 | 2020-03-20 | 海德拉生物科学有限责任公司 | 取代的黄嘌呤及其使用方法 |
| WO2016023830A1 (en) | 2014-08-11 | 2016-02-18 | Hydra Biosciences, Inc. | Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives |
| GB201702160D0 (en) | 2017-02-09 | 2017-03-29 | Univ Leeds Innovations Ltd | Inhibitors for use in therapy |
| DK3652176T3 (da) * | 2017-07-11 | 2022-01-17 | Boehringer Ingelheim Int | Substituerede xanthinderivater |
| HUE064908T2 (hu) * | 2018-12-12 | 2024-04-28 | Boehringer Ingelheim Int | Szubsztituált xantinszármazékok |
-
2019
- 2019-12-10 HU HUE19820718A patent/HUE064908T2/hu unknown
- 2019-12-10 DK DK19820718.5T patent/DK3894410T3/da active
- 2019-12-10 WO PCT/EP2019/084375 patent/WO2020120450A1/en not_active Ceased
- 2019-12-10 CN CN201980081737.1A patent/CN113166151B/zh active Active
- 2019-12-10 PL PL19820718.5T patent/PL3894410T3/pl unknown
- 2019-12-10 AU AU2019396499A patent/AU2019396499B2/en active Active
- 2019-12-10 KR KR1020217021875A patent/KR102877857B1/ko active Active
- 2019-12-10 EA EA202191588A patent/EA202191588A1/ru unknown
- 2019-12-10 EP EP19820718.5A patent/EP3894410B1/en active Active
- 2019-12-10 MX MX2021007019A patent/MX2021007019A/es unknown
- 2019-12-10 JP JP2021533340A patent/JP7502299B2/ja active Active
- 2019-12-10 ES ES19820718T patent/ES2964630T3/es active Active
- 2019-12-10 PH PH1/2021/551345A patent/PH12021551345A1/en unknown
- 2019-12-10 IL IL283768A patent/IL283768B2/en unknown
- 2019-12-10 BR BR112021008316-2A patent/BR112021008316A2/pt unknown
- 2019-12-11 US US16/710,887 patent/US11198696B2/en active Active
- 2019-12-12 TW TW108145593A patent/TWI825243B/zh active
-
2021
- 2021-06-09 CL CL2021001509A patent/CL2021001509A1/es unknown
- 2021-11-10 US US17/523,316 patent/US20220177479A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL283768A (en) | 2021-07-29 |
| IL283768B2 (en) | 2024-05-01 |
| HUE064908T2 (hu) | 2024-04-28 |
| US11198696B2 (en) | 2021-12-14 |
| DK3894410T3 (da) | 2023-11-27 |
| TWI825243B (zh) | 2023-12-11 |
| AU2019396499B2 (en) | 2024-10-10 |
| WO2020120450A1 (en) | 2020-06-18 |
| KR102877857B1 (ko) | 2025-10-29 |
| CA3119229A1 (en) | 2020-06-18 |
| CL2021001509A1 (es) | 2021-12-17 |
| KR20210102955A (ko) | 2021-08-20 |
| CN113166151B (zh) | 2023-12-01 |
| EP3894410A1 (en) | 2021-10-20 |
| PH12021551345A1 (en) | 2022-05-11 |
| JP2022512373A (ja) | 2022-02-03 |
| CN113166151A (zh) | 2021-07-23 |
| US20200190093A1 (en) | 2020-06-18 |
| MX2021007019A (es) | 2021-09-10 |
| ES2964630T3 (es) | 2024-04-08 |
| EA202191588A1 (ru) | 2021-10-18 |
| PL3894410T3 (pl) | 2024-03-18 |
| US20220177479A1 (en) | 2022-06-09 |
| JP7502299B2 (ja) | 2024-06-18 |
| EP3894410B1 (en) | 2023-10-11 |
| IL283768B1 (en) | 2024-01-01 |
| AU2019396499A1 (en) | 2021-05-27 |
| TW202039495A (zh) | 2020-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6106899B2 (ja) | 抗がん剤としての高選択性ｃ−Ｍｅｔ阻害剤 | |
| ES2903268T3 (es) | Derivados de xantina sustituida | |
| KR20160095159A (ko) | 치환된 디아미노피리미딜 화합물, 이의 조성물, 및 이를 사용한 치료방법 | |
| BR112021008316A2 (pt) | derivados de xantina substituída | |
| JP2013510903A (ja) | 治療特性を有する１，４−ベンゾジアゼピン−２，５−ジオンおよび関連化合物 | |
| CA3150465A1 (en) | Fused ring heteroaryl compounds as ripk1 inhibitors | |
| US12291532B2 (en) | Substituted xanthines as modulators of TRPC5 activity | |
| EP4201924B1 (en) | Ire1 small molecule inhibitors | |
| CA3119229C (en) | Substituted xanthine derivatives | |
| US20130184294A1 (en) | Pyrimidones for Treatment of Potassium Channel Related Diseases | |
| EA043969B1 (ru) | Замещенные ксантиновые производные | |
| BR112019025611B1 (pt) | Compostos derivados de xantina substituídos e sais dos mesmos | |
| JP2023531097A (ja) | テトラヒドロイソキノリン類誘導体の塩、その製造方法及びその医薬学的応用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |